ABLi Therapeutics
Atlanta, US · Founded 2025 · Delaware corporation
ABLi Therapeutics develops small molecule inhibitors targeting Abelson tyrosine kinases (c-Abl) to treat Parkinson's disease, Parkinson's-related neurodegenerative diseases, and other neurological conditions linked to Abl kinase dysfunction. Its RAMP drug innovation engine designs Abl kinase inhibitors, including its lead candidate risvodetinib, aimed at improved brain penetration, potency, and safety.
Founders & leadership
ABLi Therapeutics was founded in 2025 by Milton H. Werner.
MH
Milton H. WernerinChief Executive Officer, President, and Secretary
GL
Garth Lees-RolfeinChief Financial Officer and Treasurer
Board
JY
Jeffrey YoungBoard director
AD
Anastasia DaifotisBoard director
Reported raises · per SEC filings
Form D private placements$1M disclosed across 1 round · 2025
▶$1MraisedJan 2026 · 10 investors · PharmaceuticalsRule 506(b)
▶$1MraisedJan 2026 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey YoungDirector
- Milton H. WernerExecutive Officer, Director
- Garth Lees-RolfeExecutive Officer
- Anastasia DaifotisDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlapAbility7 shared keywordsAbility is a biotechnology company developing highly-selective, immune cell-modulating antibody therapeutics for patients with inflammatory diseases and cancer. Its AbiLeap discovery engine uses AI and a database of antibody sequences to generate fully-human monospecific and bispecific antibodies, with a lead program targeting inflammatory skin diseases and other candidates for solid tumors.
Bioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
ADvantage Therapeutics6 shared keywords
Abilitatx5 shared keywordsAbilita Therapeutics is a drug discovery company focused on membrane protein targets, using its EMP (Enabled Membrane Proteins) technology based on directed evolution to create stability- and expression-enhanced protein variants for discovering and optimizing drug candidates.
Abliva5 shared keywordsAbliva develops treatments for primary mitochondrial disease, a rare orphan disease caused by impaired cellular energy metabolism in the mitochondria. The company focuses on pharmaceutical research and development to address an unmet medical need where no effective treatments currently exist.
Applied Therapeutics5 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Companies competing with ABLi Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does ABLi Therapeutics do?
- ABLi Therapeutics develops small molecule inhibitors targeting Abelson tyrosine kinases (c-Abl) to treat Parkinson's disease, Parkinson's-related neurodegenerative diseases, and other neurological conditions linked to Abl kinase dysfunction. Its RAMP drug innovation engine designs Abl kinase inhibitors, including its lead candidate risvodetinib, aimed at improved brain penetration, potency, and safety.
- Who founded ABLi Therapeutics?
- ABLi Therapeutics was founded by Milton H. Werner in 2025.
- How much funding has ABLi Therapeutics raised?
- ABLi Therapeutics has disclosed $1M raised across 1 round.
- Where is ABLi Therapeutics headquartered?
- ABLi Therapeutics is headquartered in Atlanta, US.